Sugi Predict

Sugi Predict / Compounds / SCHEMBL6064148

SCHEMBL6064148

SCHEMBL6064148

CCCCCCCCCCCCCCCCC(CC=O)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRIK1 P39086 2/20 0.56
▸ GRIK2 Q13002 2/20 0.56
▸ CA2 P00918 2/20 0.53
▸ MAPK1 P28482 1/20 0.53
▸ SLC1A2 P43004 2/20 0.53
▸ SLC1A1 P43005 2/20 0.53
▸ GPR84 Q9NQS5 7/20 0.52
▸ FFAR1 O14842 1/20 0.52
▸ MAPT P10636 1/20 0.50
▸ LCK P06239 1/20 0.50
▸ PPARD Q03181 1/20 0.50
▸ ZDHHC20 Q5W0Z9 1/20 0.50
▸ ZDHHC2 Q9UIJ5 1/20 0.50
▸ ACE2 Q9BYF1 1/20 0.47
▸ SLC1A3 P43003 1/20 0.46
▸ CHRM1 P11229 1/20 0.45
▸ AKR1A1 P14550 1/20 0.45
▸ CHRM3 P20309 1/20 0.45
▸ HTR2A P28223 1/20 0.45
▸ HTR2C P28335 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6072651 1.00 GRIK1 (0.56) GRIK1GRIK2CA2MAPK1SLC1A2
SCHEMBL30802513 1.00 GRIK1 (0.56) GRIK1GRIK2CA2MAPK1SLC1A2
SCHEMBL28379864 1.00 GRIK1 (0.56) GRIK1GRIK2CA2MAPK1SLC1A2
SCHEMBL23117047 1.00 GRIK1 (0.56) GRIK1GRIK2CA2MAPK1SLC1A2
SCHEMBL8189851 1.00 GRIK1 (0.56) GRIK1GRIK2CA2MAPK1SLC1A2
SCHEMBL23116967 1.00 GRIK1 (0.56) GRIK1GRIK2CA2MAPK1SLC1A2
SCHEMBL8060953 0.92 CA2 (0.63) GRIK1GRIK2CA2MAPK1SLC1A2
SCHEMBL8326592 0.85 CA2 (0.48) GRIK1GRIK2CA2MAPK1SLC1A2
SCHEMBL9378420 0.84 CHRM1 (0.65) GRIK1GRIK2CA2MAPK1SLC1A2
SCHEMBL16062048 0.84 CHRM1 (0.65) GRIK1GRIK2CA2MAPK1SLC1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114008043-B Condensed heterocyclic compounds and their use as pest control agents PI工业有限公司 2024-06-07 — — CN disclosed
CN-115135384-B Benzimidazole compound or salt thereof, agricultural and horticultural insecticide/acaricide containing the same, and method for using the same 日本农药株式会社 2024-03-22 — — CN disclosed
CN-112119069-B Benzimidazole compound or salt thereof, agricultural and horticultural insecticide/acaricide containing the same, and method for using the same 日本农药株式会社 2023-10-03 — — CN disclosed
US-20220142972-A1 PARASITICIDAL FORMULATIONS AND USE THEREOF BAYER HEALTHCARE LLC 2022-05-12 — — US disclosed
EP-3897618-A1 PARASITICIDAL FORMULATIONS AND USE THEREOF Elanco US Inc. (US) 2021-10-27 — — EP disclosed
WO-2020132218-A1 PARASITICIDAL FORMULATIONS AND USE THEREOF BAYER HEALTHCARE LLC (US) 2020-06-25 — — WO disclosed
EP-3644968-A1 LEVOCLOPERASTINE FENDIZOATE SUSPENSION HAVING ENHANCED DISSOLUTION AND RESUSPENDABILITY Ilko Ilaç Sanayi Ve Ticaret Anonim Sirketi (TR) 2020-05-06 — — EP disclosed
WO-2019004953-A1 LEVOCLOPERASTINE FENDIZOATE SUSPENSION HAVING ENHANCED DISSOLUTION AND RESUSPENDABILITY İLKO ILAÇ SANAYI VE TICARET ANONIM ŞIRKETI (TR) 2019-01-03 — — WO disclosed
US-20060281792-A1 Parasiticide formulations suitable for dermal application SIRINYAN KIRKOR 2006-12-14 — — US disclosed
EP-1587368-A1 REPELLENT Bayer HealthCare AG (DE) 2005-10-26 — — EP disclosed
US-20030201208-A1 Dynamic superparamagnetic markers KOCH, MARTIN (DK) 2003-10-30 — — US disclosed
US-20020155140-A1 Parasiticidal formulations that can be applied dermally SIRINYAN KIRKOR (DE) 2002-10-24 — — US disclosed
US-6372765-B1 SKIN PARASITES TREATED WITH SOLVENT BAYER AKTIENGESELLSCHAFT (DE) 2002-04-16 — — US disclosed
US-6306872-B1 TREATMENT OF ANTHELMINTICS BAYER AKTIENGESELLSCHAFT (DE) 2001-10-23 — — US disclosed
US-6291472-B1 4a, 5a, 8a, 8b-tetrahydro-6H-pyrrolo[3′,4′:4, 5]furo[3,2-b] pyri-dine-6,8(7H)-dione derivatives for control of endoparasites processes for their preparation BAYER AKTIENGESELLSCHAFT (DE) 2001-09-18 — — US disclosed
US-6110928-A HUMAN OR VETERINARY MEDICINE BAYER AKTIENGESELLSCHAFT (DE) 2000-08-29 — — US disclosed
US-6001858-A INSECTICIDE FOR THE DERMAL CONTROL OF PARASITIC INSECTS ON ANIMALS BY MEANS OF AGONISTS OR ANTAGONISTS OF THE NICOTINERGIC ACETYLCHOLINE RECEPTORS OF INSECTS BAYER AKTIENGESELLSCHAFT (DE) 1999-12-14 — — US disclosed
EP-0255075-B1 2-(ACYLTHIO)METHYL DIHYDROPYRIDINES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) 1992-09-30 — — EP disclosed
US-4935433-A 2-(acylthio)methyl dihydropyridines, and pharmaceutical compositions containing them BOEHRINGER MANNHEIM ITALIA, S.P.A. (IT) 1990-06-19 — — US disclosed
EP-0255075-A1 2-(acylthio)methyl dihydropyridines, a process for their preparation and pharmaceutical compositions containing them BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) 1988-02-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220142972-A1 PARASITICIDAL FORMULATIONS AND USE THEREOF CYP51A1, SUCLG1, CUTA GRIK1 4070/4885GRIK2 3920/4885CA2 3909/4885
US-20060281792-A1 Parasiticide formulations suitable for dermal application CHRNG, CHRNE, CHRNA1 GRIK1 1948/4885GRIK2 1797/4885CA2 1540/4885
US-20020155140-A1 Parasiticidal formulations that can be applied dermally CHRNE, CHRNG, CHRNA1 GRIK1 2076/4885GRIK2 1972/4885CA2 1491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.